Key clinical point: Administration of ketorolac during primary tumor surgery was associated with a reduction of distant recurrences, particularly in overweight patients.

Major finding: Reduced recurrence was most evident in patients with high BMI (adjusted hazard ratio, 0.55; 95% CI, 0.31-0.96; P = .04).

Study details: Analysis of two retrospective series, including a total of 1,834 patients with breast cancer, evaluating intraoperative administration of ketorolac or diclofenac.

Disclosures: The authors declared no conflicts of interest.

Source: Desmedt C et al. J Natl Cancer Inst. 2018 Apr 30. doi: 10.1093/jnci/djy042.